MarginsXMarginsX
Home › Markets › Health Care › PM

Philip Morris International Inc (PM)

PM trades on NYSE in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$196.04
-1.47% on the day
Market cap
$305.6B
Mega cap
Revenue · 2025
$40.6B
+7.3% on 2024
Net income · 2025
$11.3B
27.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/0001628280-26-005939-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPM on NYSE
SectorHealth Care
Industry Medicinal Chemicals and Botanical Products
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001413329
SEC industry codeCigarettes
Incorporated inVA

Financials · 2025

LineValue
Revenue$40.6B
Net income$11.3B
Operating income$14.9B
Net margin27.9%
Operating margin36.6%
Revenue growth+7.3%
Cash$4.9B
Total assets$69.2B
P/E (computed)26.9×
P/S (computed)7.5×

Warning signs

Cash runway
Cash-flow positive
$6.7B cash at September 30, 2026
Share count, 1 year
+0.1%
2025-10-17 to 2026-10-16 · +0.4% over 3 years
Going-concern doubt
No
10-Q filed October 23, 2026
Insider net buying, 12 months
-$28.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-23
Cash and burn$6.7B cash; operating cash flow $3.8B a quarter.Report 2026-09-30
Shares outstanding1,558,655,629 (2026-10-16); 1,556,638,749 a year earlier; 1,552,405,991 three years earlier.Cover page 2026-10-16
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-08-03
AuditorPricewaterhouseCoopers AG, Lausanne, SwitzerlandPCAOB Form AP 2026-02-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $28.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$11.4B$3.3B$5.4B$6.7B$47.6B$43.1B10-Q 2026-10-23
Q2 2026
2026-06-30
$11.2B$2.8B$5.5B$6.0B$49.1B$42.5B10-Q 2026-07-24
Q1 2026
2026-03-31
$10.1B$2.4B-$399.0M$5.5B$51.9B$41.5B10-Q 2026-04-24
Q4 2025
2025-12-31
$10.4B$2.1B$4.7B$4.9B$48.8B$40.6B10-K 2026-02-06
Q3 2025
2025-09-30
$10.8B$3.5B$4.5B$4.0B$50.1B$40.0B10-Q 2026-10-23
Q2 2025
2025-06-30
$10.1B$3.0B$3.4B$4.1B$51.5B$39.1B10-Q 2026-07-24
Q1 2025
2025-03-31
$9.3B$2.7B-$350.0M$4.4B$49.6B$38.4B10-Q 2026-04-24
Q4 2024
2024-12-31
$9.7B-$579.0M$4.0B$4.2B$45.7B$37.9B10-K 2026-02-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-04-28
Latest annual report10-K2026-02-06
Latest quarterly / interim10-Q2026-10-23
Latest current report8-K2026-10-21
Latest proxyDEFA14A2026-03-31

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month-0.2%
3 months+5.3%
Year to date+24.0%
1 year+28.2%
From 52-week high-5.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medicinal Chemicals and Botanical Products

TickerCompanyPriceDayMarket cap
BTIBritish American Tobacco Industries p.l.c. Common Stock ADR$62.11+0.36%$134.2B
MOAltria Group Inc.$78.90+0.33%$131.2B
DFTXDefinium Therapeutics Inc. Common Shares$30.16-5.99%$4.1B
RGCRegencell Bioscience Holdings Limited$4.72-4.45%$2.3B
TRLVTrulieve Cannabis Corp. Subordinate Voting Shares$10.33-5.23%$2.0B
RLXRLX Technology Inc.$1.53-1.92%$1.9B
CRONCronos Group Inc. Common Share$3.27-3.25%$1.2B
OBIOOrchestra BioMed Holdings Inc.$7.12-1.79%$560.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier